IL13 and asthma: Dupilumab, a human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, effectively inhibits IL-4 and IL-13 signaling, which are crucial pathways in type 2 inflammatory diseases such as asthma [3].